Comedy and tragedy masks on red curtain background
Biotech

BioNTech, Genentech cancel ph. 2 test of personalized cancer vax

An independent safety board recommended the trial be terminated early after more deaths were observed in patients given the customized mRNA vaccine.
Darren Incorvaia Aug 28, 2026 1:50pm
fundraise tracker 2026

Fierce Biotech Fundraising Tracker '26: AusperBio, Abcuro & more

Aug 28, 2026 12:42pm
Pipette dripping water droplet with money symbol on it into test tube

AusperBio adds $120M series C to push hep B drug through ph. 3

Aug 28, 2026 10:26am
Teva

Teva saddles up as bidder for bankrupt BioXcel’s CNS assets

Aug 28, 2026 9:17am
Illustration for Fierces Chutes Ladders feature showing a blue city skyline with executives making career moves o

Vivace adds new CEO, CBO ahead of ph. 3 trial—Chutes & Ladders

Aug 28, 2026 8:30am
Genentech South San Francisco

Genentech doubles down on ADC-resistance via $1B DualityBio pact

Aug 28, 2026 4:30am
More News

With mRNA back in the spotlight, tRNA shows potential

Aug 27, 2026 2:00pm

Protein interactions shed new light on causes of autism

Aug 27, 2026 2:00pm

CEPI pushes Egyptian biotech's Ebola vaccine toward clinic

Aug 27, 2026 10:10am

Osivax bags flu vaccine rights to pursue combination shot vision

Aug 27, 2026 10:00am